Elekta AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000163628
SEK
55.85
44.17 (378.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Elekta AB stock-summary
stock-summary
Elekta AB
Pharmaceuticals & Biotechnology
Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The Company has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The Company owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).
Company Coordinates stock-summary
Company Details
Kungstensgatan 18, Box 7593 , STOCKHOLM None : 103 93
stock-summary
Tel: 46 8 58725400
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Laurent Leksell
Independent Chairman of the Board
Mr. Tomas Puusepp
Director
Ms. Caroline Leksell Cooke
Independent Director
Mr. Johan Malmquist
Independent Director
Dr. Wolfgang Reim
Independent Director
Mr. Jan Secher
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
3,646 Million
(Quarterly Results - Jul 2025)
Net Profit:
106 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 16,933 Million (Small Cap)

stock-summary
P/E

13.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

10.45%

stock-summary
Debt Equity

0.45

stock-summary
Return on Equity

15.12%

stock-summary
Price to Book

1.86